Clinical Trial Update: A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

This update describes a Phase 1 trial evaluating FLAG chemotherapy in combination with Lisaftoclax and Pelcitoclax for relapsed/refractory T-cell acute lymphobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• FLAG chemotherapy
• Lisaftoclax (APG-2575)
• Pelcitoclax (Pelcitoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase I, FLAG Chemotherapy | Phase 1 | Status: NOT_YET_RECRUITING